Therapeutic Response

PD-L1 >= 1%, Wild type ALK, and Wild type EGFR status confers therapeutic sensitivity to Ipilimumab in combination with Nivolumab in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Yervoy (ipilimumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (>=1%), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
Opdivo (nivolumab) [product monograph]. HC. Health Canada approved nivolumab in combination with ipilimumab, for the treatment of adult patients with metastatic NSCLC, expressing PD-L1 >= 1% as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.
Yervoy (ipilimumab) [product monograph]. HC. Health Canada approved ipilimumab in combination with nivolumab for the treatment of adult patients with metastatic NSCLC, expressing PD-L1 >= 1% as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.